For years, one number has had an outsized influence on conversations about ABA: 40 hours per week. It appears in discussions between providers and payers. Families hear it. Clinicians debate it. Sometimes it is treated almost as if it were a universal prescription for children with autism. But where did 40 hours actually come from? And perhaps more importantly: What does the evidence actually tell us about treatment intensity today?
I recently had the opportunity to explore these questions on the EarliPoint Exchange with Dr. Gina Green, PhD, BCBA-D, one of the most respected researchers and leaders in applied behavior analysis in the world. Our conversation moved well beyond the number of treatment hours. We talked about what decades of research actually show, why individualized care matters, how outcomes should be measured, and what providers will need to demonstrate as payer scrutiny increases.
Where Did 40 Hours Come From?
The number traces largely to the landmark 1987 Lovaas study. That study compared young children with autism who received intensive ABA—40 or more hours per week—with children receiving substantially less ABA or community services.
The outcomes were striking. Among the 19 children in the intensive treatment group, nine moved into the typical range on measures of intellectual functioning after two years of treatment. Those same nine children also completed first grade alongside typically developing peers without special support. It was an enormously important finding. But it was still one study.
As Dr. Green emphasized during our conversation, a single study answers a limited set of questions. It should generate replication, further investigation, and better questions—not become a universal prescription. And that is exactly what happened. Researchers in multiple countries subsequently conducted independent and systematic replications, comparing intensive ABA with typical services and other forms of intervention. Eventually, there was enough research to look across studies rather than relying on any one of them. That gives us a much more useful picture.
The Evidence Shows a Dose-Response Relationship
In 2010, Sigmund Eldevik and colleagues conducted a meta-analysis aggregating findings from rigorous studies of intensive ABA. Their analysis suggested that approximately 36 hours per week over two years—not precisely 40—was associated with the strongest outcomes across the studies included.
More recently, Eldevik and colleagues published an updated 2026 meta-analysis. Dr. Green described this analysis as particularly important because the researchers used individual participant data, rather than relying solely on group averages, and included studies in which the intervention clearly reflected genuine ABA. The analysis included 15 studies conducted across nine countries and examined standardized measures of intellectual functioning, adaptive functioning, and autism severity.
Treatment intensity was grouped into three categories:
- Low intensity: 5–12 hours per week
- Moderate intensity: 13–25 hours per week
- High intensity: 26 or more hours per week
The findings are consistent with a dose-response relationship, in that greater treatment intensity was associated with better outcomes. However, this evidence does not establish a single optimal treatment intensity for all children, nor does it support prescribing a fixed number of treatment hours independent of the child’s clinical presentation, developmental profile, goals, and response to intervention. Treatment intensity should therefore be individualized and informed by clinical judgment rather than determined by an arbitrary numerical threshold.
Treatment Intensity Should Be Evidence-Based—and Individualized
ABA providers are practicing in an environment where payers are increasingly focused on utilization, authorization limits, costs, and demonstrating medical necessity. At the same time, providers are seeing broad restrictions on treatment hours that may not always be connected to the scientific evidence.
We should be able to hold two ideas at once. Payers have a legitimate interest in knowing whether treatment is medically necessary, appropriately delivered, and producing meaningful outcomes. Providers also need the flexibility to recommend treatment intensity based on an individual patient’s clinical needs and the best available evidence. Blanket rules do not accomplish either goal particularly well.
A child who needs five or ten hours of focused intervention should not automatically receive 30. But a child whose clinical profile supports comprehensive, higher-intensity treatment should not automatically be limited to ten simply because that number fits a utilization policy. The question we should be asking is, “What intensity of treatment does this particular child need, and what objective evidence tells us whether it is working?”
Hours Alone Aren’t an Outcome
Treatment intensity describes how much treatment was delivered, but it does not by itself establish what changed as a result. If individualized care is the goal, outcome measurement must be individualized as well. Historically, autism intervention research has evaluated a broad range of outcomes extending beyond behavior reduction or attainment of specific treatment goals, including intellectual development, communication, adaptive functioning, social skills, autism-related characteristics, and, increasingly, family functioning and quality of life.
This broader approach is important because autism affects multiple developmental domains, and no single assessment can adequately characterize every child or capture every clinically meaningful outcome. As Dr. Green noted, the choice of assessment should be guided by factors such as age, developmental level, communication abilities, and the individual clinical presentation.
Accordingly, meaningful evaluation of treatment response requires multiple sources of information. Direct behavioral measurement remains essential, but it should be complemented by standardized, valid, and reliable assessments that help characterize development and permit clinically meaningful comparisons over time.
Why Standardized Measurement Matters
As a developmental-behavioral pediatrician, this is an area I care deeply about. Within ABA, direct measurement of specific treatment targets is a major strength and remains indispensable for ongoing clinical decision-making.
At the same time, treatment evaluation should also address a broader developmental question: whether the child’s overall functioning is changing in clinically meaningful ways. This includes examining progress in language, social communication, adaptive functioning, and other developmental domains, as well as considering whether gains are occurring at a rate that meaningfully changes the child’s developmental trajectory. At the organizational level, these same questions become important in determining whether a model of care is producing meaningful outcomes across the population of children served.
Session-level behavioral data alone cannot fully answer these broader questions. Standardized measurement therefore provides an important complementary source of information. As Dr. Green discussed, standardized assessments are developed and evaluated according to established principles of validity and reliability and can provide a consistent framework for characterizing functioning and measuring change over time.
This does not mean that standardized assessments should replace direct behavioral measurement, nor should any single standardized measure be interpreted in isolation. Rather, the strongest approach integrates individualized behavioral data with appropriate standardized measures to provide a more comprehensive assessment of treatment response and developmental progress.
ABA Has Changed. Some Fundamentals Haven’t.
A question that arose during our discussion was whether the evidence supporting intensive ABA remains applicable to contemporary service-delivery models. This is an important consideration because the field has changed substantially: much direct intervention is now delivered by technicians under BCBA supervision, payer requirements and organizational structures have evolved, and services are being delivered at a much larger scale.
At the same time, it is important not to overstate how different the early intervention literature was from current practice. Those studies did not rely exclusively on doctoral-level clinicians. Paraprofessionals, students, and caregivers often played meaningful roles in treatment delivery, and parent training has long been part of the development of ABA.
These similarities do not eliminate the need for additional research. As Dr. Green noted, contemporary service models warrant continued study, particularly models in which technicians provide a substantial proportion of direct intervention under supervision. The existing literature remains relevant, but it should be complemented by research examining the effectiveness, efficiency, and outcomes of the service-delivery structures that are most commonly used today.
The Bigger Risk: Drifting Away From the Science
One of Dr. Green’s observations that stayed with me after our conversation was her concern that, as ABA has expanded rapidly, practice may in some settings be drifting farther from the scientific principles on which the field was built. That concern deserves our attention. Scientific practice is not simply the collection of data to satisfy documentation or payer requirements; it requires confidence that what is being measured is meaningful, that assessments are appropriate for the individual patient, that interventions are supported by evidence, and that conclusions are justified by the data being collected.
At its core, this requires repeatedly asking a simple question: how do we know? How do we know that a child requires a particular level of treatment, that the intervention is producing meaningful change, that gains are generalizing beyond the treatment setting, or that a provider’s model of care is improving developmental outcomes? Likewise, how do we determine when treatment intensity should be increased, reduced, or modified? These are fundamentally scientific questions, and they are also increasingly central to payer expectations around medical necessity, treatment effectiveness, and continued authorization.
Earning Trust Through Better Evidence
The ABA field is facing a challenging moment. Payers are scrutinizing utilization more closely, providers are concerned about restrictions that may not reflect individual clinical need, and families are often caught between those competing pressures. Highly publicized cases involving improper billing have also contributed to greater skepticism about service intensity and accountability. These concerns are unlikely to be resolved by defending a single number of treatment hours. A more durable response is to make the case for evidence-based, individualized care supported by credible measures of need and outcome.
If a child requires intensive intervention, providers should be able to demonstrate the clinical basis for that intensity. If treatment is producing meaningful developmental change, that progress should be measurable. Likewise, if a child is ready for a lower intensity of care, objective assessment should help identify that change.
Framed this way, the discussion moves beyond arguments about whether more or fewer hours are inherently better and instead focuses on whether the treatment being delivered is appropriate for the individual child and producing meaningful benefit. The future of ABA should be grounded in delivering the right treatment, at the right intensity, for the right child, with sufficient evidence to determine whether it is working. That approach is more consistent with sound clinical science and may also help strengthen trust among clinicians, families, and payers.
